Baidu
map

2019 ATC:诺华的抗CD40单抗iscalimab可提高肾移植的耐受性并改善长期预后

2019-06-10 不详 MedSci原创

在美国移植大会(ATC)上,诺华的抗CD40单抗iscalimab(CFZ533)展现出提高移植肾的耐受性,并改善肾移植患者长期预后的潜力。

在美国移植大会(ATC)上,诺华的抗CD40单抗iscalimab(CFZ533)展现出提高移植肾的耐受性,并改善肾移植患者长期预后的潜力。

结果显示,与目前的标准治疗药物他克莫司相比,iscalimab显示出较低的慢性同种异体移植物损伤指数(CADI)评分,并且iscalimab治疗的5名患者中有3名(占60%)肾组织学病理检测显示正常,而他克莫司治疗的7名患者中均没有。

Iscalimab是一种全新的全人源单克隆抗体,可抑制40途径信号传导和CD40 +细胞的激活。

肝脏病学和皮肤病学全球发展部负责人埃里克休斯表示:"肾脏移植后持续的时间一般不会太久,延长移植肾脏的寿命意味着患者不需要再次透析或进行第二次移植。该临床实验的结果,让我们看到了iscalimab用于实现持久移植的潜力。"

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-12-05 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2020-01-20 snf701207
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 yankaienglish
  8. [GetPortalCommentsPageByObjectIdResponse(id=1864254, encodeId=29081864254d3, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Thu Dec 05 15:10:00 CST 2019, time=2019-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912149, encodeId=34541912149da, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jan 20 23:10:00 CST 2020, time=2020-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645611, encodeId=9cff1645611ef, content=<a href='/topic/show?id=79d99e04630' target=_blank style='color:#2F92EE;'>#长期预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97046, encryptionId=79d99e04630, topicName=长期预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e4823226485, createdName=ymljack, createdTime=Fri Jul 12 14:10:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078645, encodeId=fbfa20e8645da, content=<a href='/topic/show?id=a900550641d' target=_blank style='color:#2F92EE;'>#抗CD40单抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55064, encryptionId=a900550641d, topicName=抗CD40单抗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f5e185, createdName=zlawrance, createdTime=Tue Aug 20 17:10:00 CST 2019, time=2019-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282757, encodeId=f98c1282e57c8, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417694, encodeId=89a6141e69488, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587872, encodeId=56b2158e87272, content=<a href='/topic/show?id=cb1e1006ebd' target=_blank style='color:#2F92EE;'>#ISC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10067, encryptionId=cb1e1006ebd, topicName=ISC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=173417575755, createdName=yankaienglish, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602710, encodeId=90d41602e10ff, content=<a href='/topic/show?id=b26f29288d' target=_blank style='color:#2F92EE;'>#ATC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2928, encryptionId=b26f29288d, topicName=ATC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d4118903284, createdName=bsmagic9138, createdTime=Wed Jun 12 10:10:00 CST 2019, time=2019-06-12, status=1, ipAttribution=)]
    2019-06-12 bsmagic9138

相关资讯

2019 ASCO:AZ/MSD的PARP抑制剂Lynparza再创佳绩,晚期卵巢癌效果显着

在2019年美国临床肿瘤学会(ASCO)年会上,AstraZeneca和MSD的PARP抑制剂Lynparza(olaparib),在先前治疗过的BRCA1 / 2突变(gBRCAm)晚期卵巢癌患者客观缓解率具有统计学意义和临床意义的改善。

2019 ASCO:诺华和默克治疗MET突变非小细胞肺癌的候选药,在2期临床均显示出治疗活性

在美国ASCO大会上,诺华和默克都报告了用于治疗MET突变非小细胞肺癌(NSCLC)药物的2期临床试验结果。

2019 ADA:阿斯利康的SGLT2抑制剂达格列嗪可减轻2型糖尿病肾病

阿斯利康(AZ)在美国糖尿病协会大会(ADA)上发表的数据显示其SGLT2抑制剂Farxiga(达格列嗪)可以预防2型糖尿病的并发症,并减轻肾脏疾病的进展。

2019 ASCO:AbbVie/Roche发表其BCL-2蛋白抑制剂Venclyxto治疗白血病的阳性数据

AbbVie和Roche已经公布了CLL14试验的数据,评估BCL-2蛋白抑制剂Venclyxto(venetoclax)联合CD20单抗阿托珠单抗(obinutuzumab)治疗以前未治疗过的慢性淋巴细胞白血病患者。

2019 ADA:使用免疫疗法CD3单抗PRV-031可延迟1型糖尿病发病

新泽西州的Provention 生物制药公司,宣布其CD3单克隆抗体PRV-031(teplizumab)用于预防1型糖尿病(T1D)的临床研究结果在"新英格兰医学杂志"上在线发表,并在第79届美国糖尿病协会(ADA)会议的科学会议上进行报告。

2019年ASCO:肺癌研究,亮点合集

作为世界上最大的也是最具影响力的肿瘤组织,美国临床肿瘤学会(ASCO)紧跟研究前沿以定义更为有效、更为标准的临床护理实践。在本届ASCO年会上,诸多新研究、新理念、新方法相继问世,特别是肺癌研究,可谓干货满满。

Baidu
map
Baidu
map
Baidu
map